Global Next-Generation Sequencing (NGS) Market 2019-2024: Focus on Products & Services, Applications, Technology, 18 Countries Data, Industry Insights, and Competitive Landscape – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Next-Generation Sequencing Market: Focus on Products and Services,
Applications, Technology, 18 Countries Data, Industry Insights, and
Competitive Landscape – Analysis and Forecast, 2019-2024”

report has been added to ResearchAndMarkets.com’s
offering.

The global next-generation sequencing market was $4.93 billion in 2018
and is estimated to grow over $9.91 billion by 2024. The global
next-generation sequencing market is expected to grow with a
double-digit compound annual growth rate between the years 2019 and 2024.

With a substantial increase in the demand for genome mapping programs
and diagnostics tests based on sequencing, the NGS market is expected to
witness impressive growth and promises to be a lucrative field for
investment. In terms of products, the kits and consumables sub-segment
dominated the global next-generation sequencing market in 2018. However,
the software sub-segment is expected to witness the highest CAGR in the
forecast period from 2019 to 2024.

The reversible terminator sequencing technology currently dominates the
global NGS market. Nanopore technology is estimated to witness the
highest CAGR in the forecast period.

And by application, presently, the pharmaceuticals field holds the
largest share of the global next-generation sequencing market and is
expected to grow at 13.22% CAGR in the forecast period from 2019 to
2024. However, with the growing demand for non-invasive diagnostic
procedures, the diagnostic field is expected to witness an impressive
CAGR in the forecast period from 2019 to 2024.

The global next-generation sequencing market is segmented by
geographical regions into North America, Europe, Asia-Pacific, Latin
America, and Rest-of-the-World (RoW). North America is the leading
contributor to the global next-generation sequencing market and
contributed to 48% of the global market values in 2018. However,
Asia-Pacific is expected to grow at a CAGR of 17.25% in the forecast
period 2019-2024. Moreover, the Asia Pacific market contributed
approximately 18.95% of the total global market value in 2018.

A paradigm shift in the dynamics market is expected in 2023 with the
introduction of portable technologies in full scale. The leading players
in the market are taking necessary steps to tackle the shift in the
dynamics and sustain in the competition. The global next-generation
sequencing market is majorly dominated by U.S. players. Companies
belonging to the U.S., such as Illumina, Inc., and Thermo Fisher
Scientific, contributed to more than 70% of the market value in 2018.

The key players which have significant contributions to the NGS market
are 10x Genomics, Agilent Technologies, Inc., bioMrieux SA, Bio-Rad
Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG,
GenapSys, Inc., Illumina, Inc., New England Biolabs, Inc., NuGEN
Technologies Inc., Oxford Nanopore Technologies Limited, Pacific
Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN, and Thermo
Fisher Scientific, among others.

The field of service providers for sequencing tests and the applications
based on genome sequencing are perceived to be a lucrative business
across the globe. With the impressive rise in the demand for
sequencing-based diagnostics applications, namely non-invasive prenatal
testing, companion diagnostics, and liquid biopsy, the service providing
companies have gained popularity and acceptance across the globe.
Additionally, substantial investments are being made in bioinformatics
startups and service providing companies.

With the growing demand for genome mapping programs, a large pool of
genomic data is being generated, and the key players of the market are
seeking help from the bioinformatics startups to meet the market
requirement. Service providing companies help in expanding the global
reach of the key players of the market and also play a significant role
in increasing the adoptability of sequencing technologies across the
globe.

Some of the opportunities on which significant work is being carried out
presently in the market are a hybridization of technologies and
development of portable technologies. The best sequencer is the one with
the ability to sequence long reeds, in short run time and with great
accuracy. The present available sequencers on the market possess any one
of the mentioned features, but not all three.

In spite of the substantial investments made by prominent companies to
develop the instruments with the aforementioned features, it is not
expected to be the reality at any time soon. Thus, the hybridization of
available technologies, such as SMRT and reversible semiconductor
sequencing technology, is acknowledged to be a promising approach to
cater to the needs of the market.

Key Topics Covered

Executive Summary

1 Market Overview

1.1 The Basic NGS Workflow

1.2 Historical Trends

1.3 Comparative Analysis of Sanger Sequencing and Next-Generation
Sequencing

1.4 Global NGS Market Scenario

1.5 Assumptions and Limitations

2 Market Dynamics

2.1 Impact Analysis

2.2 Market Drivers

2.2.1 Growing Demand for Non-Invasive Diagnosis

2.2.2 Technological Advancements in the Field of Computational Biology

2.2.3 Growing Prominence of Precision Medicine

2.3 Market Restraints

2.3.1 Uncertain Reimbursement and Regulatory Policies

2.3.2 Expensive Sequencing Procedures and Their Applications in Medical
Treatments

2.3.3 High Capital Requirement Hampering the Expansion of Global Reach

2.4 Market Opportunities

2.4.1 Development of Portable Technologies

2.4.2 Hybridization of Technologies

2.4.3 Technological Developments in the Field of Bioinformatics and
Automation Software

3 Competitive Landscape

3.1 Key Strategies and Developments

3.1.1 Product Launch and Enhancements

3.1.2 Collaborations, Partnership, Joint Ventures, and Agreements

3.1.3 Mergers and Acquisition

3.1.4 Business Expansion and Others

3.2 Market Share Analysis (2016 and 2017)

3.2.1 Market Share Analysis, by Company, by Instruments

3.2.2 Market Share Analysis, by Company, by Kits and Consumables

3.3 Growth Share Analysis

3.3.1 Growth Share Analysis (by Products)

3.3.2 Growth Share Analysis (by Sequencing Instruments Provider)

3.4 Value Chain Analysis

3.4.1 Value Chain Analysis of Medical Device Industry

3.4.2 Value Chain Analysis: Illumina, Inc.

3.5 $100 per Genome: Era of Predictive and Personalized Medicine

3.6 Industry Attractiveness

4 Industry Insights

4.1 Emerging Companies and Leading Investors of NGS Market

4.2 Legal Requirements and Regulations

4.3 Role of Service Provider in the Next-Generation Sequencing Market

5 Global NGS Market (by Product Type)

5.1 Instruments

5.2 Kits and Consumables

5.2.1 Supply Chain of NGS Kits and Consumables

5.2.1.1 Key Challenges for MedTech Supply Chain

5.2.1.2 Supply Chain Model: Next-Generation Sequencing Market

5.2.1.3 Thermo Fisher Scientific

5.2.1.4 QIAGEN N.V.

5.2.1.5 PerkinElmer, Inc.

5.2.1.6 Pacific Biosciences of California, Inc.

5.2.1.7 Oxford Nanopore Technologies Limited.

5.2.1.8 NuGEN Technologies, Inc.

5.2.1.9 New England Biolabs, Inc.

5.2.1.10 Illumina, Inc.

5.2.1.11 F. Hoffmann-La Roche AG

5.2.1.12 Danaher Corporation

5.2.1.13 ASURAGEN, Inc,

5.2.1.14 Agilent Technologies, Inc.

5.2.1.15 Adaptive Biotechnologies.

5.2.1.16 10x Genomics

5.3 Software

6 Global NGS Market (by Technology)

6.1 Reversible Terminator Sequencing

6.2 Ion Torrent Semiconductor Sequencing

6.3 Single Molecule Real Time Sequencing (SMRT)

6.4 Nanopore Sequencing Technology

6.5 Others

7 Global NGS Market (by Application)

7.1 Pharmaceuticals

7.2 Diagnostics

7.3 Agricultural and Animal Research

7.4 Forensics

7.5 Others

8 Global NGS Market (by Region)

8.1 North America

8.2 Europe

8.3 Asia-Pacific

8.4 Latin America

8.5 Rest-of-the-World

9 Company Profiles

9.1 Overview

9.2 10x Genomics

9.2.1 Company Overview

9.2.2 Role of 10x Genomics in the Global NGS Market

9.2.3 SWOT Analysis

9.3 Agilent Technologies Inc.

9.4 Bio-Rad Laboratories Inc.

9.5 BGI

9.6 bioMerieux S.A.

9.7 Danaher Corporation

9.8 F. Hoffmann-La Roche AG

9.9 Illumina Inc.

9.10 New England Biolabs Inc.

9.11 NuGEN Technologies Inc.

9.12 Oxford Nanopore Technologies Limited

9.13 Pacific Biosciences of California Inc.

9.14 QIAGEN N.V.

9.15 PerkinElmer Inc.

9.16 Thermo Fisher Scientific

10 Research Scope and Methodology

11 Annexures

11.1 Annexure I: Key Developments and Strategies (January 2014 to
February 2019)

11.2 Annexure II: Product Mapping

For more information about this report visit https://www.researchandmarkets.com/r/iyohbi

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Molecular
Diagnostics